Latest HBV Stories
GENEVA, May 20, 2014 /PRNewswire/ -- The International Federation of Pharmaceutical Manufacturers and Associations [http://www.ifpma.org ] (IFPMA) has published today a
MILFORD, Mass., May 12, 2014 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical
DOYLESTOWN, Pa., May 8, 2014 /PRNewswire/ -- Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus
CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr.
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
--BioCrossroads Joins Twilight Ventures, Luson Bioventures and Other Investors-- INDIANAPOLIS, BLOOMINGTON, Ind.
Small financial incentives, totaling as little as £30, can dramatically increase the likelihood of people who inject drugs completing a course of hepatitis B virus (HBV) vaccination.
Data to be presented in April at the European Association for the Study of the Liver Meeting CARLSBAD, Calif., March 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.